| Literature DB >> 34234879 |
Li-Li Wang1, Li Ding2, Peng Zhao1, Jing-Jing Guan1, Xiao-Bin Ji1, Xiao-Li Zhou1, Shi-Hong Shao1, Yu-Wei Zou1, Wei-Wei Fu1, Dong-Liang Lin1.
Abstract
BACKGROUND: Morule-like component (MLC) was a rare structure in primary lung adenocarcinoma. We aimed to reveal the clinicopathological, radiological, immunohistochemical, and molecular features of lung adenocarcinoma with MLCs.Entities:
Mesh:
Substances:
Year: 2021 PMID: 34234879 PMCID: PMC8216805 DOI: 10.1155/2021/9186056
Source DB: PubMed Journal: Dis Markers ISSN: 0278-0240 Impact factor: 3.434
Clinicopathologic characteristics of lung adenocarcinomas with MLCs.
| Case no. | Age (years)/sex/smoking | Location | Size (cm) | Histologic findings | Treatment | TNM stage | Follow-up (months) | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Proportion of MLCs (%) | Predominant component | Other components | STAS | Visceral pleural invasion | |||||||
| 1 | 50/F/no | LLL | 2.2 | 10 | Acinar | Micropapillary | — | — | Lobectomy | T1N1M0 | AWT (45) |
| 2 | 46/F/no | RLL | 2.5 | 15 | Acinar | Micropapillary | + | — | Lobectomy | T1N0M0 | NET (38) |
| 3 | 68/F/no | LUL | 3.0 | 20 | Acinar | Micropapillary | — | + | Lobectomy | T2N0M0 | NET (37) |
| 4 | 46/F/no | RUL | 2.5 | 5 | Acinar | Lepidic/micropapillary | — | — | Lobectomy | T1N0M0 | NET (37) |
| 5 | 48/M/yes | LUL | 2.0 | 5 | Lepidic | Acinar | + | — | Lobectomy | T1N1M0 | NET (34) |
| 6 | 66/M/yes | LLL | 3.2 | 15 | Lepidic | Papillary/cribriform | — | — | Lobectomy | T2N1M0 | DOT(22) |
| 7 | 55/F/no | RLL | 3.1 | 10 | Lepidic | Papillary | — | — | Lobectomy | T2N0M0 | NET (33) |
| 8∗ | 51/M/no | RLL | 1.2 | 15 | Lepidic | Acinar | — | — | Lobectomy | T1N1M0 | NET (32) |
| 9 | 56/F/no | LUL | 1.0 | 20 | Papillary | Lepidic | — | — | Lobectomy | T1N0M0 | NET (32) |
| 10 | 53/M/yes | LLL | 2.0 | 15 | Lepidic | Cribriform | — | + | Lobectomy | T2N1M0 | DOT (3) |
| 11 | 68/F/no | LUL | 2.5 | 25 | Lepidic | Acinar | — | — | Lobectomy | T1N0M0 | NET (30) |
| 12 | 60/M/no | LLL | 2.0 | 5 | Lepidic | Acinar/micropapillary | — | — | Wedge resection | T1N0M0 | NET (30) |
| 13 | 56/M/yes | LLL | 3.4 | 15 | Lepidic | Papillary/micropapillary/acinar | + | + | Lobectomy | T2N1M0 | NET (29) |
| 14 | 68/F/yes | RML | 1.3 | 5 | Lepidic | Cribriform/micropapillary | + | — | Lobectomy | T1N0M0 | NET (28) |
| 15 | 55/F/no | LUL | 2.5 | 35 | Acinar | Micropapillary | + | — | Lobectomy | T1N0M0 | Lost to follow-up |
| 16 | 70/F/no | RUL | 2.3 | 50 | Acinar | None | — | + | Wedge resection | T2N0M0 | NET (28) |
| 17 | 61/M/no | RUL | 3.0 | 10 | Acinar | Micropapillary | — | — | Lobectomy | T1N1M0 | NET (27) |
| 18 | 48/F/no | LUL | 2.8 | 5 | Lepidic | Acinar | — | + | Lobectomy | T2N0M0 | NET (27) |
| 19 | 66/F/yes | LUL | 2.5 | 10 | Acinar | Lepidic | — | + | Lobectomy | T2N0M0 | NET (27) |
| 20 | 68/F/no | RLL | 1.7 | 5 | Papillary | Lepidic | — | — | Lobectomy | T1N0M0 | NET (26) |
AWT: alive with tumor (recurrence); DOT: died of tumor; F: female; LLL: left lower lobe; LUL: left upper lobe; M: male; NET: no evidence of tumor; RLL: right lower lobe; RML: right middle lobe; RUL: right upper lobe; STAS: spread through air spaces. ∗This case was a minimally invasive adenocarcinoma.
Figure 1CT imaging of lung adenocarcinomas with MLCs. CT scans showed a solid mass in almost all patients (a–c). A well-defined solid mass in case 1 (a). A spiculated solid mass in case 3 (b). A lobular solid mass in case 16 (c). A mass composed of the central solid component and peripheral ground-glass opacity in case 12 (d).
Figure 2Histological findings of lung adenocarcinomas with MLCs. The MLCs were composed of spindle cells showing a whorled growth pattern, and the spindle cells in the MLCs had a syncytial appearance (a). The MLCs showed a streaming growth pattern with fenestration which was similar to the usual ductal hyperplasia in the breast (b). A few MLCs were epithelioid (c). An MLC in a papillary adenocarcinoma (d). MLCs and micropapillary components in a lepidic adenocarcinoma (e). The transitional region between the cribriform component and the MLC (f).
Immunohistochemical features of adenocarcinoma with MLCs.
| Antibody | MLC | Adjacent tumour area |
|---|---|---|
| CK7 | 20 (100%) | 20 (100%) |
| TTF-1 | 20 (100%) | 20 (100%) |
| Napsin-A | 20 (100%) | 20 (100%) |
| E-cadherin | 20 (100%) | 20 (100%) |
| Vimentin (V9) | 20 (100%) | 6 (30%) |
| Vimentin (EP21) | 20 (100%) | 6 (30%) |
|
| ||
| Membranous | 20 (100%) | 20 (100%) |
| Cytoplasmic and nuclear | 0 | 0 |
| CK5/6 | 0 | 0 |
| p40 | 0 | 0 |
| p63 | 0 | 0 |
| Synaptophysin | 0 | 0 |
| Chromogranin A | 0 | 0 |
| Cdx-2 | 0 | 0 |
| Ki-67 index | 1%-10% | 1%-10% |
Figure 3The MLCs were positive for CK7, TTF-1, napsin-A, and E-cadherin (a–d). Vimentin was always positive in the MLCs (e). β-Catenin showed membranous staining in all cases (f). The MLCs were negative for p63 (g). ALK immunopositivity showed cytoplasmic granular staining in a case harboring ALK-EML4 fusion (h). Her-2 immunopositivity showed membranous staining in the case harboring HER2 amplification (i).
Figure 4The driver mutation status in lung adenocarcinomas with MLCs.
Figure 5Kaplan-Meier analysis showing the role of MCLs in the prognosis of lung adenocarcinoma. No significant difference in OS was detected between the lung adenocarcinoma with MCLs and without MCL.